Multiple drug classes currently in Phase III clinical development for NAFLD/NASH target the diverse pathophysiology associated with metabolic liver disease including fibroblast growth factor analogs, PPAR transcription factors, bile acid receptors, SGLT2 inhibitors (Ala, 2021), GLP-1 receptors and thyroid hormone receptors (Sinakos et al., 2022). Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.